https://doi.org/10.4081/reumatismo.2021.1395
Red cell distribution width is a potential predictor of early relapse in polymyalgia rheumatica
Submitted: 11 January 2021
Accepted: 15 March 2021
Published: 3 August 2021
Accepted: 15 March 2021
Abstract Views: 2680
PDF: 511
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Red blood cell distribution width (RDW) has been studied as a prognostic biomarker for different chronic inflammatory diseases. In this paper we aim to evaluate its potential role in the prediction of early relapse in patients affected by polymyalgia rheumatica (PMR). We revised retrospectively clinical records of patients who received a diagnosis of PMR, according to 2012 ACR/EULAR classification criteria, for whom baseline clinical and laboratory data were available. The baseline RDW variation coefficient was correlated to the risk of relapse, in the first 6 months of the disease. We identified 44 patients [females 15 (34.0%)/males 29 (66.0%); median age 80 (72-83)], 9 of whom had an early relapse. These patients showed a larger median RDW than patients who did not relapse [13.7 (13.5-14.9)% vs 13.5 (12.7-14.2)%; p=0.04). The two groups were comparable for all the other clinical and laboratory parameters considered. Interestingly, patients in the higher half of the RDW distribution showed a shorter relapse-free survival (p<0.03). In a stepwise logistic regression, RDW (p=0.01) predicted the risk of relapse at 6 months, while age, gender, CRP, ESR, Hb, MCV and prednisone dose did not fit the model. Our results show that RDW is an independent biomarker of early relapse, making this parameter a potentially promising predictive marker in PMR.
Hu ZD, Lippi G, Montagnana M. Diagnostic and prognostic value of red blood cell distribution width in sepsis: A narrative review. Clin Biochem. 2020; 77: 1-6.
DOI: https://doi.org/10.1016/j.clinbiochem.2020.01.001
Tonelli M, Sacks F, Arnold M, et al.; for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 2008; 117: 163-8.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.727545
Patel KV, Ferrucci L, Ershler WB, et al. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med. 2009; 169: 515-23.
DOI: https://doi.org/10.1001/archinternmed.2009.11
Zorlu A, Bektasoglu G, Guven FM, et al. Usefulness of admission red cell distribution width as a predictor of early mortality in patients with acute pulmonary embolism. Am J Cardiol. 2012; 109: 128-34.
DOI: https://doi.org/10.1016/j.amjcard.2011.08.015
Zou XL, Lin XJ, Ni X, et al. Baseline red blood cell distribution width correlates with disease activity and therapeutic outcomes in patients with systemic lupus erythematosus, irrespective of anemia status. Clin Lab. 2016; 62: 1841-50.
DOI: https://doi.org/10.7754/Clin.Lab.2016.160213
Hu ZD, Sun Y, Guo J, et al. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjögren's syndrome. Clin Biochem. 2014; 47: 287-90.
DOI: https://doi.org/10.1016/j.clinbiochem.2014.08.022
Yunchun L, Yue W, Jun FZ, et al. Clinical significance of red blood cell distribution width and inflammatory factors for the disease activity in rheumatoid arthritis. Clin Lab. 2016; 62: 2327-31.
DOI: https://doi.org/10.7754/Clin.Lab.2016.160406
Bellan M, Giubertoni A, Piccinino C, et al. Red Cell Distribution Width and Platelet Count as Biomarkers of Pulmonary Arterial Hypertension in Patients with Connective Tissue Disorders. Dis Markers. 2019; 2019: 4981982.
DOI: https://doi.org/10.1155/2019/4981982
Bellan M, Soddu D, Zecca E, et al. Association between red cell distribution width and response to methotrexate in rheumatoid arthritis. Reumatismo. 2020; 72: 16-20.
DOI: https://doi.org/10.4081/reumatismo.2020.1243
Muratore F, Pazzola G, Pipitone N, Salvarani C. Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Rev Clin Immunol. 2016; 12: 1037-45.
DOI: https://doi.org/10.1080/1744666X.2016.1178572
Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012; 71: 484-92.
DOI: https://doi.org/10.1016/j.ymed.2012.09.009
Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). Clin Chem Lab Med. 2015; 53: 2015-9.
DOI: https://doi.org/10.1515/cclm-2015-0155
Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015; 74: 1799-807.
DOI: https://doi.org/10.1136/annrheumdis-2015-207578
Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017; 12: 621-7.
DOI: https://doi.org/10.1007/s11739-017-1626-8
Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015; 74: 1808-17.
DOI: https://doi.org/10.1136/annrheumdis-2015-207578
Nakamura H, Kamada K, Tarumi M, et al. Gadolinium-enhanced magnetic resonance imaging in shoulders contributes accurate diagnosis and predicting recurrence to patients with polymyalgia rheumatica. Clin Exp Rheumatol. 2020 Mar 28 [Epub ahead of print].
Hattori K, Hirano Y, Kojima T. Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis. 2020; 23: 1581-6.
DOI: https://doi.org/10.1111/1756-185X.13978
Birra D, Bosello SL, Peluso G, Zoli A. Sixth-month remission as a predictor for twelve-month remission in polymyalgia rheumatica. Clin Exp Rheumatol. 2020; 38: 436-41.
How to Cite
Soddu, D., Sola, D., Bellan, M., Boin, E., Cittone, M., Zecca, E., … Sainaghi, P. (2021). Red cell distribution width is a potential predictor of early relapse in polymyalgia rheumatica. Reumatismo, 73(2), 117–121. https://doi.org/10.4081/reumatismo.2021.1395
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli, Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients , Reumatismo: Vol. 64 No. 6 (2012)
- G. Guggino, A. Ferrante, F. Macaluso, G. Triolo, F. Ciccia, Pathogenesis of polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- F. Muratore, C. Salvarani, P. Macchioni, Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- B.D. Nielsen, B. Dasgupta, Perspectives and unmet needs in polymyalgia rheumatica. Providing the fundamental framework for the development of new treatment regimes in polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- C. Chatzigeorgiou, S.L. Mackie, Comorbidity in polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- S. Muller, S. Hider, T. Helliwell, R. Partington, C. Mallen, The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- D. Camellino, C. Dejaco, Update on treatment of polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- N. Possemato, C. Salvarani, N. Pipitone, Imaging in polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- A. Sobrero, C. Manzo, A. Stimamiglio, The role of the general practitioner and the out-of-hospital public rheumatologist in the diagnosis and follow-up of patients with polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- K. Stefanantoni, I. Sciarra, M. Vasile, R. Badagliacca, R. Poscia, M. Pendolino, C. Alessandri, C.D. Vizza, G. Valesini, V. Riccieri, Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension , Reumatismo: Vol. 66 No. 4 (2014)
You may also start an advanced similarity search for this article.
